Please select the option that best describes you:
Which patients with metastatic HER2 negative, PD-L1 <1% esophageal cancer patients, would you utilize paclitaxel/ramucirumab maintenance?
Would you continue initial capecitabine until progression, after dropping oxaliplatin to avoid neuropathy, or transition to paclitaxel/ramucirumab as per the ARMANI trial?